TreeFrog Therapeutics develops proprietary C-Stem™ technology to produce scalable, high-quality cell therapies, including a lead program targeting Parkinson’s disease. The company addresses the need for effective and safe regenerative medicine by enabling the production of billions of cells in a single batch, facilitating clinical trials and patient access.
Funding
$84.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cell therapy manufacturing methods often struggle to produce the large cell quantities needed for clinical trials and widespread patient access, particularly for sensitive cell types. Traditional 2D culture systems lack scalability and can result in inconsistent cell quality, limiting the potential of regenerative medicine.
Solution
TreeFrog Therapeutics offers C-Stem™, a proprietary technology platform designed for scalable production of high-quality cell therapies. C-Stem™ utilizes a biomimetic encapsulation process, generating over 1,000 capsules per second in a GMP-compliant manner. This enables seeding of up to 10-liter bioreactors, delivering up to 15 billion cells in a single batch. The resulting 3D microtissues exhibit enhanced cell survival post-graft, effective dose control, and superior quality control, making the technology suitable for a range of regenerative medicine applications.
Target Audience
The primary target audience includes biotech and pharmaceutical companies developing cell therapies, as well as researchers and clinicians in the regenerative medicine field.
Features
- High-throughput encapsulation technology capable of generating over 1,000 capsules per second
- Scalable bioreactor integration, enabling production of billions of cells per batch
- 3D microtissue format for enhanced cell survival and therapeutic efficacy
- GMP-compliant process suitable for clinical-grade cell therapy manufacturing
- Proprietary cell therapy pipeline, including a lead program targeting Parkinson’s disease
- Out-licensing agreements available for C-Stem™ technology